Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Finance

23 January 2019

GenSight Biologics Reports its Cash Position as of December 31, 2018

10 Jan 2019 - 11 Jan 2019

Oddo BHF Forum, Lyon, France

07 Jan 2019 - 10 Jan 2019

37th Annual J.P. Morgan Healthcare Conference, San Francisco (CA), USA

24 October 2018

GenSight Biologics Reports its Cash Position as of September 30, 2018

09 October 2018

GenSight Biologics to participate in multiple upcoming investor conferences

22 Nov 2018 - 23 Nov 2018

Salon Actionaria 2018, Paris, France

09 Oct 2018

Chardan 2nd Annual Genetic Medicines Conference, NYC (US)

25 July 2018

GenSight Biologics Reports Interim Financial Results for the First Half of 2018

25 April 2018

GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010

28 February 2018

GenSight Biologics Reports Full Year 2017 Financial Results

  • View previous 9 articles
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page